Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2
01/03/2024 23:04
March 1 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ :
* MEZZION PHARMACEUTICALS ANNOUNCES DR. RAHUL RATHOD OF
BOSTON
CHILDREN'S HOSPITAL AND HARVARD MEDICAL SCHOOL AS THE GLOBAL
PRINCIPAL INVESTIGATOR FOR THE CONFIRMATORY PIVOTAL PHASE 3
TRIAL FUEL-2
Source text for Eikon: ID:nPnxY0xSa
Further company coverage: 140410.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2